retatrutide and autoimmune disease Retatrutide—A Game Changer in Obesity Pharmacotherapy Can GLP-1 Drugs Boost Immunity?

While OTC alternatives remain uniform and untailored, genetic insights can support a more personalized conversation between you and your provider about whether prescription-strength options align with your metabolic profile

Microbiome-focused support may be particularly relevant for people who are experiencing digestive side effects from GLP-1 medications and looking for ways to improve their comfort during treatment

We recognize that symptoms like low energy and motivation can result from various causesincluding other health conditions, lifestyle factors, sleep disorders, or mental health concerns

Health Technol Assess 2004

Examples include AstraZenecas investment in Eccogene and Roches agreement to buy GLP-1 drug developer Carmot Therapeutics for up to $3.1bn in December 2023